Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abemaciclib - Eli Lilly and Company

Drug Profile

Abemaciclib - Eli Lilly and Company

Alternative Names: Abemaciclib mesylate; Bemaciclib; Bemaciclib mesylate; LY-2835219; Verzenio; Verzenios

Latest Information Update: 16 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Dana-Farber Cancer Institute; Eli Lilly; Eli Lilly and Company; Jules Bordet Institute; M. D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; Washington University School of Medicine
  • Class Aminopyridines; Antineoplastics; Benzimidazoles; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Brain cancer; Cholangiocarcinoma; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Glioblastoma; Liposarcoma; Mantle-cell lymphoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Urogenital cancer
  • Phase I/II Head and neck cancer
  • Phase I Cancer; Non-small cell lung cancer; Renal cell carcinoma

Most Recent Events

  • 20 Dec 2019 Phase-I clinical trials in Prostate cancer (Combination therapy, Late-stage disease, Metastatic disease) in Japan (PO) (NCT04071262)
  • 02 Dec 2019 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in Australia, USA (PO) (NCT04165031)
  • 21 Nov 2019 Eli Lilly and Company plans a phase I/II trial for Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA, Australia, Canada, Spain (PO) (NCT04165031)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top